The CEO of BioNTech Ugur Sahin was inoculated in early 2021 with the COVID-19 vaccine his team developed with Pfizer, a ...

The Nobel Prize-winning scientific innovation underlying the COVID-19 vaccine proved to be a notable financial boon for the ...

Moderna stock surged Tuesday after the Centers for Disease Control and Prevention noted a two-week spike in positive Covid tests.

That’s more than $1.2 billion in unpaid royalties BioNTech is expected to pay for the Pfizer-BioNTech COVID-19 vaccine sales.

The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...

Researchers have discovered that the SARS-CoV-2 spike protein persists in the brain and skull bone marrow for years after ...

Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.

BioNTech (BNTX) stock slipped after signing $1B deals with NIH and the University of Pennsylvania to resolve COVID vaccine ...

Five years after the start of Covid, we appear to be trying to teach ourselves the lessons of the pandemic the hard way.

Scientists discover that SARS-CoV-2 spike protein remains in the brain and skull bone marrow for years post-infection, ...

According to earlier statements by BioNTech, the dispute with the university was about "non-exclusive rights" to patent applications used in the Covid-19 vaccine from BioNTech and Pfizer.

The BioNTech/Pfizer jab was the first COVID-19 vaccine to be authorized by a stringent regulatory authority for emergency use and the first to be approved for regular use.